Increased Expression of Secreted Form A Disintegrin and Metalloproteinase 28 (ADAM28s) in Esophageal Squamous Cell Carcinoma: Implication for Carcinoma Cell Proliferation via Interleukin 6 Receptor Shedding.

Keita Kouzu¹, Satsuki Mochizuki², Hironori Tsujimoto¹, Yusuke Ishibashi¹, Ines P Nearchou³, Kentaro Ohara⁴, Seiichiro Fujishima¹, Yoji Kishi¹, Susumu Matsukuma⁵, Yasunori Okada⁶, Hideki Ueno¹

¹Department of Surgery, National Defense Medical College, Saitama, Japan.

²Department of Surgery, National Defense Medical College, Saitama, Japan. Electronic address: s-mochi@ndmc.ac.jp.

³Indica Labs Inc., New Mexico, New Mexico.

⁴Department of Pathology, Keio University School of Medicine, Tokyo, Japan.

⁵Department of Laboratory Medicine, National Defense Medical College, Saitama, Japan.

⁶Department of Pathophysiology for Locomotive Diseases, Juntendo University Graduate School of Medicine, Tokyo, Japan.

PubMed DOI

Abstract

A disintegrin and metalloproteinase 28 (ADAM28), which comprises membrane-anchored form (ADAM28m) and short-secreted form (ADAM28s), is overexpressed by carcinoma cells and involved in cancer cell proliferation and metastasis in several cancers. However, little is known about the implications of ADAM28 in esophageal squamous cell carcinoma (ESCC). In this study, we investigated the expression and…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.